InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,066.40
(
0.28%
)
Dow Jones
39,357.01
(
-0.36%
)
Brent Oil
81.34
(
-0.32%
)
Bitcoin
59,209.75
(
-0.25%
)
Post# of 97239
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Investor100

Send PM Follow Ignore
Followers 505
Posts 6242
Boards Moderated 0
Alias Born 09/20/2006

Investor100

Re: Investor100 post# 39925

Friday, 02/18/2011 9:21:54 AM

Friday, February 18, 2011 9:21:54 AM

Post# of 97239
PLX:Protalix BioTherapeutics - Awaiting FDA Decision

(RTTNews) - Israeli biotech firm Protalix BioTherapeutics Inc. (PLX: News ) is only days away from the scheduled US regulatory decision on its investigational gaucher (pronounced Go-shay) drug Taliglucerase Alfa.

Gaucher disease is an inherited genetic disorder, in which patients lack the normal form of glucocerebrosidase, or GCD enzyme that breaks down specific fat molecules. The lack of this enzyme results in the accumulation of fat in liver, spleen and bone marrow. The disease affects about 1 in 100,000 persons in the general population. According to the National Gaucher Foundation, 2,500 Americans suffer from gaucher disease.

http://www.rttnews.com/Content/TopStories.aspx?Id=1555477&SM=1

Investor 100
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up